SB
NAVB

Suntrust Banks’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Suntrust Banks’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-512
Closed -$18K – 1790
2014
Q1 		$18K Hold
512
– – ﹤0.01% 1898
2013
Q4 		$21K Hold
512
– – ﹤0.01% 1827
2013
Q3 		$27K Buy
+512
New +$29.8K ﹤0.01% 1810

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Suntrust Banks's NAVB Position: Q2 2014 in Review

Suntrust Banks sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2014, closing a stake of 512 shares — an estimated $18K sold.

Suntrust Banks first reported a position in NAVB in Q3 2013 and held it in 3 quarters. The position peaked at $27K in Q3 2013. 87 funds tracked by Wall St. Rank hold NAVB as of Q2 2014.

  • Suntrust Banks reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2014 after selling out during the quarter.
  • Suntrust Banks sold 512 Navidea Biopharmaceuticals Inc. shares in Q2 2014, an estimated $18K.
  • Suntrust Banks first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2013 and held it in 3 quarters.
  • Suntrust Banks's Navidea Biopharmaceuticals Inc. position peaked at $27K in Q3 2013.
  • 87 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2014.

Based on Suntrust Banks's 13F filing for Q2 2014, filed 14 Aug 2014.